Nils Tore Vethe
- Researcher, Section Leader; PhD
- +47 23 07 40 55
Publications 2024
The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation
Br J Clin Pharmacol (in press)
DOI 10.1111/bcp.16170, PubMed 39056476
The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study
Atheroscler Plus, 55, 31-38
DOI 10.1016/j.athplu.2024.01.001, PubMed 38293288
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Eur Heart J Cardiovasc Pharmacother, 10 (4), 307-315
DOI 10.1093/ehjcvp/pvae001, PubMed 38196131
Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor
Ther Drug Monit, 46 (3), 416-417
DOI 10.1097/FTD.0000000000001209, PubMed 38648662
Publications 2023
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms
Clin Pharmacol Ther, 113 (4), 887-895
DOI 10.1002/cpt.2844, PubMed 36622792
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease
Pharmacol Res Perspect, 11 (3), e01089
DOI 10.1002/prp2.1089, PubMed 37186070
[New tool for interpreting pharmacogenetic analyses]
Tidsskr Nor Laegeforen, 143 (13)
DOI 10.4045/tidsskr.23.0496, PubMed 37753760
Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients
Br J Clin Pharmacol, 89 (12), 3690-3701
DOI 10.1111/bcp.15870, PubMed 37537150
Publications 2022
Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects
J Intern Med, 291 (6), 891-893
DOI 10.1111/joim.13454, PubMed 35103360
Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma
Ther Drug Monit, 44 (4), 558-567
DOI 10.1097/FTD.0000000000000992, PubMed 35482468
Publications 2021
Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients
J Pharm Biomed Anal, 203, 114216
DOI 10.1016/j.jpba.2021.114216, PubMed 34182411
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Ther Drug Monit, 43 (2), 150-200
DOI 10.1097/FTD.0000000000000871, PubMed 33711005
The Question of Accuracy Versus Interlaboratory Agreement for Monitoring the Immunosuppressants Everolimus and Sirolimus
Ther Drug Monit, 43 (3), 444-446
DOI 10.1097/FTD.0000000000000892, PubMed 33840796
Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study
Ther Drug Monit, 43 (3), 371-375
DOI 10.1097/FTD.0000000000000873, PubMed 33596033
The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease
Atherosclerosis, 336, 23-29
DOI 10.1016/j.atherosclerosis.2021.09.020, PubMed 34610521
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects
BMC Cardiovasc Disord, 21 (1), 596
DOI 10.1186/s12872-021-02422-7, PubMed 34915854
In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance
Basic Clin Pharmacol Toxicol, 129 (6), 427-436
DOI 10.1111/bcpt.13645, PubMed 34396687
Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
Ther Drug Monit, 43 (2), 247-255
DOI 10.1097/FTD.0000000000000835, PubMed 33181621
Publications 2020
Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123628, PubMed 33287390
Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
Clin Transl Sci, 13 (6), 1327-1335
DOI 10.1111/cts.12833, PubMed 32652886
Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
Ther Drug Monit, 42 (3), 407-414
DOI 10.1097/FTD.0000000000000697, PubMed 31479042
Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
Br J Clin Pharmacol, 86 (6), 1100-1112
DOI 10.1111/bcp.14218, PubMed 31925806
Salting Out-Assisted Liquid-Liquid Extraction for Liquid Chromatography-Tandem Mass Spectrometry Measurement of Tacrolimus, Sirolimus, Everolimus, and Cyclosporine a in Whole Blood
Ther Drug Monit, 42 (5), 695-701
DOI 10.1097/FTD.0000000000000794, PubMed 32701594
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
Ther Drug Monit, 42 (5), 665-670
DOI 10.1097/FTD.0000000000000780, PubMed 32520841
Publications 2019
Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
Cell Transplant, 28 (12), 1603-1613
DOI 10.1177/0963689719872488, PubMed 31512504
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther Drug Monit, 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640, PubMed 31045868
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br J Clin Pharmacol, 85 (12), 2878-2885
DOI 10.1111/bcp.14122, PubMed 31495943
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand Cardiovasc J, 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085, PubMed 31030568
Pharmacogenetics in personalised drug therapy
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0055, PubMed 31062549
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702
Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
Ther Drug Monit, 41 (5), 607-614
DOI 10.1097/FTD.0000000000000655, PubMed 31584926
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther Drug Monit, 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578, PubMed 30633723
Publications 2018
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther Drug Monit, 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539, PubMed 30086087
Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies
Ther Drug Monit, 40 (3), 292-300
DOI 10.1097/FTD.0000000000000510, PubMed 29578937
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Am Heart J, 208, 37-46
DOI 10.1016/j.ahj.2018.10.005, PubMed 30530121
Publications 2017
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br J Clin Pharmacol, 83 (11), 2494-2502
DOI 10.1111/bcp.13367, PubMed 28686294
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther Drug Monit, 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439, PubMed 28749817
Publications 2016
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
DOI 10.1155/2016/4196460, PubMed 26885529
Publications 2015
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
DOI 10.1016/j.clinbiochem.2015.10.001, PubMed 26453533
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
DOI 10.1111/tri.12617, PubMed 26046470
Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations
Ther Drug Monit, 37 (5), 675-80
DOI 10.1097/FTD.0000000000000185, PubMed 25565673
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382
Publications 2014
More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients
Transplantation, 97 (12), 1266-71
DOI 10.1097/01.TP.0000443225.66960.7e, PubMed 24521776
Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
Ther Drug Monit, 36 (1), 46-53
DOI 10.1097/FTD.0b013e31829dcb66, PubMed 24081206
Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid
Ther Drug Monit, 36 (1), 108-18
DOI 10.1097/FTD.0b013e3182a13900, PubMed 24061448
Publications 2013
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand J Clin Lab Invest, 73 (2), 117-24
DOI 10.3109/00365513.2012.745947, PubMed 23281843
Publications 2012
Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial
BMC Res Notes, 5, 418
DOI 10.1186/1756-0500-5-418, PubMed 22871021
Publications 2011
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol Dial Transplant, 26 (11), 3767-72
DOI 10.1093/ndt/gfr153, PubMed 21471328
Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects
Ther Drug Monit, 33 (4), 402-10
DOI 10.1097/FTD.0b013e3182241799, PubMed 21743383
[Drug interactions and immunosuppression in organ transplant recipients]
Tidsskr Nor Laegeforen, 131 (20), 2000-3
DOI 10.4045/tidsskr.11.0138, PubMed 22016125
Publications 2010
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
Scand J Clin Lab Invest, 70 (8), 583-91
DOI 10.3109/00365513.2010.531141, PubMed 21039189
Publications 2009
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
Transplantation, 87 (8), 1221-4
DOI 10.1097/TP.0b013e31819f1001, PubMed 19384170
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
DOI 10.1186/1479-5876-7-64, PubMed 19635156
Molecular pharmacodynamics of the immunosuppressant mycophenolic acid: a basis for monitoring and individualized treatment
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 741, 1 b. (flere pag.)
BIBSYS 091766974, ISBN 978-82-8072-780-0
Publications 2008
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
DOI 10.1097/01.tp.0000296854.68123.03, PubMed 18192912
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int Immunopharmacol, 9 (2), 173-80
DOI 10.1016/j.intimp.2008.10.017, PubMed 19010451
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand J Clin Lab Invest, 68 (4), 277-85
DOI 10.1080/00365510701724871, PubMed 18609073
Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals
Ther Drug Monit, 30 (6), 647-55
DOI 10.1097/FTD.0b013e31818955c3, PubMed 18806697
Publications 2007
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
DOI 10.1093/ndt/gfm632, PubMed 17956893
Publications 2006
Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy
Ther Drug Monit, 28 (5), 608-13
DOI 10.1097/01.ftd.0000245680.38143.ca, PubMed 17038874
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Scand J Clin Lab Invest, 66 (1), 31-44
DOI 10.1080/00365510500420259, PubMed 16464785
Publications 2002
Effekten av mykofenolat på IMP-dehydrogenase ved immunsuppressiv behandling av nyretransplanterte pasienter
N.T. Vethe, Oslo, 59, vi s.
BIBSYS 022449574